Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
11 studies found for:    matulonis
Show Display Options
Rank Status Study
1 Recruiting GSK1120212+GSK2141795 for Cervical Cancer
Condition: Cervical Cancer
Interventions: Drug: GSK1120212 (trametinib);   Drug: GSK2141795
2 Recruiting Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Conditions: Ovarian Cancer;   Breast Cancer
Interventions: Drug: BKM120 and Olaparib;   Drug: BYL719 and Olaparib
3 Completed AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer;   Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer;   Stage I Ovarian Epithelial Cancer;   Stage II Ovarian Epithelial Cancer
Interventions: Drug: cediranib maleate;   Other: laboratory biomarker analysis;   Other: pharmacological study
4 Active, not recruiting Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Conditions: Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Cabozantinib S-malate;   Drug: Paclitaxel;   Other: Laboratory Biomarker Analysis
5 Recruiting A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
Condition: Platinum Sensitive Ovarian Cancer
Interventions: Drug: Active comparator: Niraparib;   Drug: placebo
6 Completed Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer
Conditions: Ovarian Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer;   Mesodermal Tumors
Interventions: Drug: Paclitaxel;   Drug: Carboplatin
7 Active, not recruiting Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Interventions: Drug: Avastin;   Drug: cyclophosphamide
8 Completed Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Interventions: Drug: Carboplatin;   Drug: Pemetrexed
9 Withdrawn Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Intervention: Drug: Olaparib
10 Terminated Vorinostat, Carboplatin and Gemcitabine Plus Vorinostat Maintenance in Women With Recurrent, Platinum-Sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Interventions: Drug: Vorinostat;   Device: Carboplatin;   Drug: Gemcitabine
11 Recruiting First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors
Condition: FOLR-1 Positive Solid Tumors
Intervention: Drug: IMGN853

Indicates status has not been verified in more than two years